The Fc fusion protein market thrives on innovative therapies targeting oncological and genetic disorders. Key opportunities lie in developing stable and soluble treatments, partnering with research ...
"Emerging Fusion Protein Technologies Drive Innovation in Targeted Therapies Across Autoimmune, Cancer, Metabolic, and Cardiovascular Diseases" Boston, Dec. 11, 2025 (GLOBE NEWSWIRE) -- According to ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...
BUFFALO, N.Y., — Many childhood cancers start with a hijacking at the molecular level. A group of abnormal proteins known as fusion proteins aberrantly engage with a collection of proteins that ...
A study looking at the biophysical properties of an abnormal protein driving cancer cells is giving scientists new therapeutic clues for how to treat ependymoma, the third most common childhood brain ...
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...
Research originally authored by Kanvasri Jonnalgadda, Lam R. Markely, Scott Estes, Shashi Prajapati at High-Throughput Analytical Group (HTAG)-Cell Culture Development, Biogen IDEC, Cambridge, and MA ...
CRDMO WuXi Biologics and HanchorBio, a clinical-stage biotech company focusing on immunotherapies for oncology and autoimmune diseases, signed a collaboration agreement to support the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results